A Current Review of Targeted Therapeutics for Ovarian Cancer

Hindawi Publishing Corporation Journal of Oncology Volume 2010, Article ID 149362, 11 pages doi:10.1155/2010/149362 Review Article A Current Review of Targeted Therapeutics for Ovarian Cancer Susana M. Campos1 and Sue Ghosh2 1 Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA 2 Brigham Correspondence should be addressed to Susana M. Campos, [email protected] Received 9 July 2009; Accepted 28 September 2009 Academic Editor: Maurie M. Markman Copyright © 2010 S. M. Campos and S. Ghosh. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Difficult to detect, ovarian cancer typically presents at an advanced stage. Significant progress has been achieved in the treatment of ovarian cancer with therapeutics focused on DNA replication or cell division. However, despite sensitivity to induction chemotherapy the majority of patients will develop recurrent disease. Conventional agents for recurrent disease offer little in terms of long-term responses. Various targeted therapeutics have been explored in the management of ovarian cancer. These include monoclonal antibodies to epidermal growth factor receptors, small molecule tyrosine kinase inhibitors, monoclonal antibodies directed at the vascular endothelial growth factor (bevacizumab), and the small tyrosine kinase inhibitors that target the vascular endothelial growth factor receptor. Recently, several other agents have come forth as potential therapeutic agents in the management of ovarian cancer. These include monoclonal antibodies to the folate receptor, triple angiokinase inhibitors, PARP inhibitors, aurora kinase inhibitors, inhibitors of the Hedgehog pathway, folate receptor antagonists, and MTOR inhibitors. 1. Introduction 2. Angiogenesis Various targeted therapeutics have been explored in the management of ovarian cancer. These include monoclonal antibodies to Her 2 neu [1, 2] and other epidermal growth factor receptors [3] (i.e., Trastuzumab [1], Pertuzumab [2], and EMD 7200 [3]), small molecule tyrosine kinase inhibitors that targeted the various EGFR receptors (gefitinib [4], erlotinib [5], CI-1033 [6]), monoclonal antibodies directed at the vascular endothelial growth factor [7–19] (bevacizumab), and the small tyrosine kinase inhibitors that target the vascular endothelial growth factor receptor [20–25]. Recently, several other agents have come forth as potential therapeutic agents in the management of ovarian cancer. These include monoclonal antibodies to the folate receptor, triple angiokinase inhibitors, PARP inhibitors, aurora kinase inhibitors, inhibitors of the Hedgehog pathway, folate receptor antagonists, and MTOR inhibitors. This paper will explore the current data on the various targeted approaches in ovarian cancer. Attention will be directed at understanding the molecular mechanisms of these agents balanced with their application to clinical practice. Enthusiasm for cytotoxic agents in the management of ovarian cancer has been tempered by the emergence of resistance. As such, a focus on alternative innovative therapeutics has emerged. One such direction is the inhibition of angiogenesis. Angiogenesis is one of the cardinal processes leading to invasion and metastasis of solid tumors. The angiogenic-signaling pathway may be triggered by the release of angiogenic ligands such as the vascular endothelial growth factor from tumor cells. Tumor angiogenesis is well established as essential for the growth and metastasis of solid tumors, [26–28] This process involves the recruitment of mature vasculature and circulating endothelial cells [29, 30] and proangiogenic soluble mediators one of which includes the vascular endothelial growth factor (VEGF) [31]. This factor has several known activities [31], such as mitogenesis, angiogenesis, endothelial survival, enhancement of vascular permeability, and effects on hemodynamic status. In ovarian cancer increased levels of VEGF are associated with poor prognosis and have been confirmed in multivariate analysis as an independent prognostic indicator of survival [28, 32– 38]. Given the poor long-term responses appreciated with 2 conventional cytotoxic agents that target VEGF have taken center stage. Agents targeting angiogenesis include monoclonal antibodies to the VEGF ligand [7–19], small tyrosine kinase inhibitors that target the vascular endothelial growth factor receptor [20–25], and soluble decoy VEGF receptors [39, 40]. The most studied agent to date has been bevacizumab, a recombinant humanized monoclonal antibody to the VEGF ligand. To date several investigators [7–19] (Table 1) have explored bevacizumab as a single agent or in combination with chemotherapy in the management of advanced ovarian cancer. Several studies in both the upfront and in the recurrent setting are underway. GOG 218 is a randomized placebo controlled three-arm study examining the role of bevacizumab in combination with carboplatin and paclitaxel and also as a maintenance therapy. ICON-7 is a two arm trial comparing carboplatin and paclitaxel (six cycles) versus carboplatin, paclitaxel, and bevacizumab (7.5 mg/kg) for six cycles followed by 12 cycles of maintenance bevacizumab. Campos et al. [20] is conducting a phase II trial of carboplatin/paclitaxel/bevacizumab in optimally and suboptimally debulked patients. Patients achieving a clinical complete response, partial response, or stable disease are subsequently randomized to either bevacizumab for 12 months or the combination of bevacizumab and erlotinib. Preliminary safety results have noted an increase in hypertension but to date no evidence of gastrointestinal perforations. Given the recent data that has emerged on the role on intraperitoneal chemotherapy [41–43] investigators are exploring the role of IP chemotherapy with IV bevacizumab. Several abstracts were highlighted at the recent American Society of Clinical Oncology meeting. Konner et al. [44] and McKeekin et al. [45] in independent studies reported the feasibility of utilizing bevacizumab (IV) in conjunction with intraperitoneal therapy. One bowel perforation [44] was noted the Konner study while McKeekin et al. [45] colleagues noted one deep venous thrombosis and one fistula. In the recurrent setting several trials are being conducted. The OCEANS trial is a randomized study of carboplatin/gemcitabine and bevacizumab (NCT 00434642) versus carboplatin/gemcitabine. GOG 213 (Figure 1) is randomized trial in recurrent ovarian cancer patients. Patients are stratified as to whether or not they are surgical candidates. If the patients are deemed to be surgical candidates they are randomized to surgery or no surgery followed by randomization to chemotherapy. If patients are randomized to no surgery they are subsequently randomized to carboplatin and paclitaxel or carboplatin/paclitaxel and bevacizumab. The combination of carboplatin/DOXIL and bevacizumab is also being studied. The later trial may prove to be intriguing given the recently reported results of the CALYPSO trial [46]. In the CALYPSO trial the combination of Carboplatin-Doxil demonstrated a superior therapeutic index (benefit/risk ratio) versus current standard, carboplatin-paclitaxel. Journal of Oncology Surgical candidate or not Surgery Yes No Randomize Randomize No surgery Carboplatin + paclitaxel Carboplatin + paclitaxel + bevacizumab Chemo randomization Figure 1: GOG 213. 3. Small Molecules that Target the VEGFR Receptor Small molecule tyrosine kinase inhibitors that target the vascular endothelial growth factor receptor are currently being investigated in numerous clinical trials. AZD2171 (Cediranib) is a novel oral tyrosine kinase inhibitor of VEGFR2, VEGFR1, and c-kit. Matulonis et al. [21] reported the initial results of this agent in the management of patients with recurrent ovarian cancer. Five patients had confirmed partial responses with an overall response rate of 18.5%. Three patients had stable disease lasting 30, 27+, and 24 weeks. Hirte et al. [22] reported a response rate of 40.5% in platinum sensitive patients and a response rate of 29% in platinum resistance disease with AZD 2171 (Cediranib). Prevalent side effects included fatigue and hypertension. Currently, ICON-6 is conducting a study of AZD2171 (Cediranib) in platinum sensitive relapsed ovarian cancer in a three arm randomized placebo-controlled phase III trial in combination with paclitaxel and carboplatin. (Figure 2). Pazopanib is tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR) −1, −2, and −3, platelet-derived growth factor receptor (PDGFR) −α and −β, and c-Kit. Friedlander et al. [24] have reported activity with pazopanib in women with advanced epithelial ovarian cancer. Eleven of 36 subjects (31%) experienced a cancer antigen-125 (CA-125) response to pazopanib. Overall response rate based on modified Gynecologic Cancer Intergroup (GCIG) criteria (incorporating CA-125, Response Evaluation Criteria in Solid Tumors (RECIST), and clinical assessment) was 18% in subjects with measurable disease at baseline and was 21% in subjects without measurable disease at baseline. Median PFS was 84 days. Sunitinib, an inhibitor that targets the VEGFR 1, 2, 3, and platelet–derived growth factor receptors, has also been studied in the management of patients with recurrent ovarian cancer. Biagi et al. [25] investigated the role of sunitinib in the management of patients with recurrent ovarian cancer. Sunitinib was administered at 50 mg every Journal of Oncology 3 Table 1: Current trials in ovarian/fallopian/peritoneal cancer. Author Burger R et al. [7] Cannistra et al. [8] Garcia et al. [9] Wright et al. [10] Chura et al. [11] Nimeiri et al. [12] Monk et al. [13] Simpkins et al. [14] McGonigle et al. [15] Azad et al. [17] Micha et al. [16] Campos/Penson et al. [18, 19] N 62 44 70 23 15 13 32 25 18 13 20 58 Prior lines 1-2 2-3 1–3 2–15 5–15 1–3 2–10 2–12 0–2 NR 0 0 Platinum S/R∗ /first line +/+ +/+ +/+ −/+ +/+ +/+ −/+ −/+ −/+ NR First line First line Regimen∗∗ Single Single Combo Combo Combo Combo Single Combo Combo Combo Combo Combo RR:CR + PR 21 % 15.9% 24% 35 % 43 % 15 % 16 % 28 % 22% 46% 80% 75% TTP/PFS median PFS 4.7mo PFS 4.4 mo TTP 7.2 mo TTP 5.6 mo PFS 3.9 mo PFS 4.1 mo PFS 5.5 mo TTP 9.0 mo PFS 3.8 mo NR NR PFS:11mo ∗ Enrolled patients: platinum sensitive/resistant/first line. bevacizumab or combination therapy with cytotoxic or other biological agents. NR: not reported. ∗∗ Single Carboplatin/paclitaxel + placebo followed by placebo for 18 months Carboplatin/paclitaxel + Cediranib followed by placebo for 18 months ICON 6 Randomized Carboplatin/paclitaxel + Cediranib followed by Cediranib for 18 months Figure 2: ICON-6. day on a 4-week on 2-week off schedule. Noted in this study was the development of pleural effusions during the 2-week rest period. Of the seventeen patients that were studied 12% of patients had a partial response, and 59% of patients had disease stabilization. Currently the Harvard Cancer Center Gynecological Group (NCT00768144) is conducting a phase II trial using sunitinib in refractory ovarian caner patients. The dose of sunitinib is held constant at 37.5 mg every day. AMG 706 is an investigational inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, plateletderived growth factor receptor, and stem-cell factor receptor. A Phase II Evaluation of AMG706 (NCT00574951) in the Treatment of Persistent or Recurrent Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer is currently active. Matei et al. [26] reported on the activity of sorafenib in patient with recurrent ovarian cancer. Sorafenib is a tyrosine kinase inhibitor targeting raf and other receptor kinases (VEGF-R, PDGF-R, Flt3, c-KIT). Patients received sorafenib at 400 mg QD. Patients in this study have a 3% partial response, and 20% of patients had stable disease for > than 6 months. Toxicities included rash, metabolic abnormalities, gastrointestinal, cardiovascular, and pulmonary toxicity. 4. VEGF Trap (Aflibercept) VEGF trap (Aflibercept) is fusion protein containing the VEGF binding regions of both VEGFR-1 and 2 linked through the Fc region of a human IgG1. Aflibercept binds VEGF-A and neutralizes all VEGF-A isoforms plus placental growth factor. This agent is currently being explored in platinum resistant ovarian cancer. Columbo et al. [39] reported the results of VEGF Trap in patients with symptomatic malignant ascites. Aflibercept, 4 mg/kg, i.v. was administered every 2 weeks, in patients with advanced ovarian cancer and symptomatic ascites requiring frequent paracentesis. Primary endpoint was repeat paracentesis response rate (RPRR) defined as at least a doubling of time to the first paracentesis compared to a baseline average. Patients received 1–13 cycles of aflibercept. The authors reported that the time to the first paracentesis was 12–205 days. Eight out of ten evaluable patients achieved a RPRR response as per protocol. Adverse events included bowel obstruction, nausea, vomiting, anorexia, edema, and 1 case of bowel perforation. Tew et al. [40] reported the preliminary results of a randomized phase II study in patients with recurrent platinum-resistant epithelial ovarian cancer. VEGF Trap was (2 or 4 mg/kg) administered intravenously every 2 weeks in patients with recurrent 4 ovarian cancer was conducted. Five partial responses in a sample size of 45 patients (11%) were reported. 5. Epidermal Growth Factor Inhibitors In addition to the VEGF inhibitors, the epidermal growth factor receptor (EGFR) has emerged as an attractive target [47–49]. The activation of EGFR signaling pathways is known to increase proliferation, angiogenesis, and decrease apoptosis. Several strategies that target the EGFR in gynecologic cancers have included monoclonal antibodies [1–3], (trastuzumab, pertuzumab, EMD7200) and tyrosine kinases inhibitors [4–6] (gefitinib, erlotinib, lapatinib and CI-1033). Bookman and colleagues [1, 50] reported a response rate of 7% in a phase II trial of ovarian cancer patients treated with trastuzumab. Kaye et al. [51], Amler et al. [52], and Makhija et al. [53] in independent studies examined pertuzumab, a humanized recombinant monoclonal antibody that inhibits the dimerization of HER2 with EGFR, HER 3, and HER4, in patients with ovarian cancer. As a single agent there were only modest responses. Gordan et al. [54] recently published the clinical activity of pertuzumab in advanced ovarian cancer. There were five partial responses (response rate 4.3%), eight patients (6.8%) with stable disease lasting at least 6 months, and 10 patients with CA-125 reduction of at least 50%. Median progression-free survival (PFS) was 6.6 weeks. Twenty eight percent of the tumor biopsies were pHER2+ by ELISA. Of note the progression free survival for pHER2+ patients was 20.9 weeks (n = 8) versus 5.8 weeks for pHER2−. Several studies are ongoing. The EORTC have recently completed a trial investigating erlotinib as maintenance therapy following first-line chemotherapy in patients with ovarian cancer (NCT00263822). A phase II open label trial of erlotinib and bevacizumab is being conducted by Alberts et al. in patients with advanced ovarian cancer (NCT00696670). Unlike other disciplines there is lack of data in the gynecological literature on who, if any, will benefit from EGFR inhibitors. Schilder et al. [55] reported that in a sample size of 55 ovarian cancer patients 3.6% had mutations in the EGFR tyrosine kinase domain and that the mutation correlated with a response to gefitinib. Exploratory analyses in the pertuzumab studies [51–53] suggested that patients with platinum resistant disease and low levels of HER3 mRNA might benefit from pertuzumab. An additional study by Tanner et al. [56] demonstrated an influence of HER 3 expression on the survival of patients with ovarian cancer. Selection of ovarian cancer patients with EGFR amplifications, increased pHER2, and low expression of HER 3 ratios may represent the selected few that may respond to EGFR inhibitors. Journal of Oncology nation of EGFR inhibitors and VEGF inhibitors. Nimeiri et al. [12] investigated the clinical activity and safety of bevacizumab and erlotinib patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer. In this study patients were heavily pretreated. Two patients had a fatal bowel perforation. Currently investigators at the Harvard Cancer Center are conducting a randomized phase II trial of Bevacizumab or Bevacizumab and Erlotinib as First Line Consolidation Chemotherapy after Carboplatin, Paclitaxel, and Bevacizumab (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer & Papillary Serous Mullerian Tumors (NCT00520013) [20]. 7. Platelet Derived Growth Factor Inhibitors Platelet-derived growth factor (PDGF) a prototype for understanding the function of growth factors and receptor tyrosine kinases (TK) [58] induces cell growth and survival, transformation, migration, vascular permeability, and wound healing [59]. PDGF receptor (PDGFR) activation in cancer occurs as a consequence of gene amplification, chromosomal rearrangements, or activating mutations [60– 62]. PDGFR activation is critical to tumor initiation in addition to functioning as a mediator of connective tissue stroma [63]. PDGFR has been shown in 50–80% of ovarian tumors [63]. Several agents that target the PDGFR have been studied. These include imatinib mesylate [63–66], sorafenib, [17, 26], sunitinib [25], dasatinib [67], 3G3 [68], and CDP 860 [69]. Imatinib mesylate is a selective Abl, c-Kit, and PDGFR inhibitor. Three phase II clinical trials [64, 70, 71] in patients with ovarian cancer failed to demonstrate clinical benefit. The GOG (170 M) is currently studying dasatinib in a Phase II Evaluation of Dasatinib in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma BIBF1120 [72] is a novel agent. It is a triple angiokinase inhibitor that targets the VEGFR, PDGRF, and the fibroblast growth factor receptor (FGFR). Sustained pathway inhibition is a distinct feature of this agent. Ledermann et al. [73] recently conducted a randomized phase II placebocontrolled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer. The 36-week PFS rate for BIBF 1120 was 15.6% and 2.9% for placebo. The authors concluded that maintenance BIBF 1120 could delay disease progression in ovarian cancer patients who had previously responded to chemotherapy. 8. Folate Receptor Inhibitors 6. Combination Therapy with EGFR and VEGF Inhibitors EGFR activation has been reported to promote VEGF [57] secretion. Several clinical studies are exploring the combi- Folic acid is an essential vitamin and of importance for one-carbon transfer processes medicated by enzyme systems involved in DNA synthesis [74]. Increased expression of α-FR has been described in various tumor tissues, including ovarian, endometrial, and breast cancer [75]. While the Journal of Oncology 5 Table 2: PDGF-targeted therapies in ovarian cancer. clinical trial.gov ID NCT00913835 NCT00768144 NCT00437372 NCT00792545 NCT00672295 NCT00436215 NCT00526799 NCT00390611 NCT00096200, NCT00510653 NCT00840450 Therapeutic regimen Doxil ± IMC 3G3 in platinum refractory or resistant EOC Sunitinib in refractory/recurrent ovarian, fallopian tube, or peritoneal cancer Sunitinib and radiation therapy Dasatinib + bevacizumab in surgically metastatic, or unresectable solid tumors Dasatinib + paclitaxel + carboplatin in ovarian, fallopian tube, and peritoneal cancer Sorafenib + bevacizumab in recurrent/refractory ovarian, fallopian tube, or peritoneal cancer Sorafenib + topotecan in platinum resistant EOC Paclitaxel + carboplatin ± sorafenib for first-line therapy for EOC Sorafenib + paclitaxel + carboplatin in recurrent platinum-sensitive ovarian, fallopian tube, or peritoneal cancer Gleevac study for patients with ovarian cancer Gleevac and paclitaxel with recurrent mullerian cancers function of α-FR in cancers is not fully understood, folates are critical metabolites for nucleotide synthesis and methylation reactions. Its overexpression might confer a tumor growth advantage by increasing folate availability to cancer cells [75]. Over 90% of nonmucinous ovarian cancers overexpress α-FR [76]. Several strategies have been employed to target the folate receptor. Some of these include the use of anti-α-FR antibodies or folic acid conjugates. There has also been recent research to show that α-FR may have a potential as a target for immunotherapeutic approaches in ovarian cancer. α-FR is a tumor-associated antigen that induces detectable immune responses in 70% of patients with breast and ovarian cancer [77]. The presence of endogenous immune reactivity raises the possibility that the immune response could be further enhanced by vaccines targeting the α-FR. Hernando et al. [78] presented a case of a women with recurrent epithelial ovarian cancer treated with a vaccination regimen created with autologous dendritic cells engineered with mRNAencoded α-FR [78]. An initial contrast-enhanced CT of the abdomen before vaccination had shown para-aortic lymph node metastasis at the level of the left renal hilus and lower abdominal aorta. Follow-up CT 16 months after last vaccination depicted a more than 50% regression of lymph node metastasis and a dramatic decrease in CA125 concentrations 4 weeks after the first vaccination [78]. Farletuzumab (MORAb-003) is a monoclonal antibody to α-FR that activates antibody-dependent cell-mediated cytotoxicity and complement-mediated toxicity [79]. In a recent Phase II trial of 54 patients [80] with platinumsensitive relapsed disease patients who received combination therapy exhibited a prolongation of their remission when compared to their previous remission. Ongoing clinical trials looking at Farletuzumab include a Phase III trial comparing the efficacy and safety of intravenous carboplatin and taxanes with and without farletuzumab in subjects with first platinum-sensitive relapse, a Phase II trial examining intravenous paclitaxel with and without farletuzumab in patients with first platinum-resistant or refractory relapse. Study PI W. McGuire S. Campos A . Dicker E. Kohn A. Secord E. Kohn D. Matei J. Hainsworth V. von Gruenigan D. Gershenson F. Muggia EC145 is a drug that is specifically designed to enter cancer cells via the folate vitamin receptor (FR). Early clinical evidence in a small number of phase I patients suggests that EC145 may have antitumor effect in women with advanced ovarian cancer. Current independent studies include a study of EC145 in patients with advanced ovarian and endometrial cancers (NCT00507741) and a study in patients with platinum resistant ovarian cancer with a combination of Doxil and EC145 Combination Therapy (NCT00722592). 9. Poly-ADP-Ribose Polymerase (PARP) Inhibitors Between 5 and 10% of all ovarian cancer cases are associated with inheriting a mutation in the BRCA1 or BRCA2 gene [81]. The lifetime risk of ovarian cancer for BRCA1 and BRCA2 mutation carriers is estimated at 40–50% and 10– 20%, respectively. BRCA1 and BRCA2 are essential for the repair of double strand DNA breaks (DSBs) and maintenance of genomic stability [82]. Poly (ADP-ribose) polymerase (PARP) is a key nuclear enzyme involved in the repair of DNA single-strand breaks (SSBs) using the base excision repair pathway [83]. PARP-1 and PARP-2 are the only members of the PARP family known to be activated by DNA damage, and PARP-1 has been best characterized. PARP inhibition results in the accumulation of DNA SSBs, which may lead to DSBs. Thus, the use of PARP inhibitors in BRCA mutation carriers uses the concept of synthetic lethality and hence can be described a therapeutic exploitation. In the first human phase I clinical trial using Olaparib (AZD2281, KU-0059436; AstraZeneca) an oral smallmolecule PARP-1 inhibitor, toxicities included nausea, vomiting, anorexia, and fatigue. Efficacy has been reported. Olaparib has shown antitumor activity in BRCA-associated ovarian cancer [84, 85]. Fifty patients were treated at various doses, of which 41 were BRCA1 mutation carriers, eight were 6 Journal of Oncology Table 3: α-folate receptor inhibitors and ovarian cancer. Clinical trial.gov ID NCT00722592 NCT00738699 NCT00849667 Therapeutic regimen Doxil and EC145in platinum resistant EOC MORAb-003 in first platinum resistant or refractory relapsed EOC MORAb-003 in platinum sensitive, first relapse EOC BRCA2 mutation carriers and one had a compelling family history for BRCA mutation. Of the 46 patients with evaluable disease, 41% reached either a complete or partial response. Eleven percent had meaningful stabilization of disease for 4 months, giving a total clinical benefit rate of 52%. The median response duration was 30 weeks. Recently reported were the results of a phase II trial of the oral PARP inhibitor Olaparib (AZD 2281) in BRCAdeficient advanced ovarian cancer [86]. An international, phase II study examined two cohorts of patients that received oral olaparib in 28-day cycles, initially at the MTD, 400 mg bid (33 pts), and subsequently at 100 mg bid (24 pts). The confirmed overall response rate was 33% at 400 mg bid dose and 12.5% at 100 mg bid dose. Clinical benefit rate (ORR and/or confirmed ≥50% decline in CA125) was 57.6% at 400 mg bid and 16.7% at 100 mg bd. Toxicity was mild. Olaparib is currently being evaluated in randomized Phase II trials in platinum-sensitive recurrent ovarian cancer, and in known BRCA or high grade recurrent ovarian cancer. It is also being compared with pegylated liposomal doxorubicin in patients with BRCA mutated ovarian cancer with a 0-12 month platinum-free interval (NCT00628251). Other PARP inhibitors are also being evaluated in BRCA mutation carriers with cancer, including AG0146999 (Pfizer) ABT888 (Abbott), BSI-201 (Bipar), INO-1001 (Inotek/Genentech), and MK4827 (Merck). The use of PARP inhibitors might be extended to sporadic ovarian cancers with homologous recombination defects. These sporadic tumors seem to phenocopy BRCA1/2 deficient tumors even though they do not possess the germline mutations in either gene. This phenomenon is called “BRCAness.” This can occur due to loss of heterozygosity, hypermethlyation, and haploinsufficiency (inactivation of one BRCA allele), thereby, genetically silencing the BRCA gene without an actual germline mutation. A recent study suggests that over 50% of high-grade serous ovarian cancer had loss of BRCA function, either by genetic or epigenetic events [87]. A randomized placebo-controlled trial of olaparib as a maintenance therapy in patients with serous (sporadic) ovarian cancer at high risk for recurrence is now underway. 10. Aurora Kinase Inhibitors Aurora kinases are protein kinases that are important mitotic regulators [88, 89]. They are central to many cellular functions notably mitosis, centromere separation, as well as mitotic spindle formation. Three aurora kinases (A, B, C) exist. The activity of aurora kinase is cell cycle dependent and Study PI R. Messmann D. Chakraborty D. Chakraborty active during the G2M phase of the cell cycle. Several investigators [88, 90, 91] have described the oncogenic potential of these proteins. Aurora-A also phosphorylates the tumor suppressor protein p53, resulting cell cycle progression [92]. Aurora A is overexpressed in 83% of human epithelial ovarian carcinomas [93]. In addition, amplification of human chromosome 20q13.2, which contains Aurora-A, frequently occurs in ovarian cancer [94]. Aurora kinase A has been significantly associated with tumor grade, FIGO stage, and survival [93, 95]. Lin et al. [96] studied the role of MK-0457, a small molecule pan-aurora kinase inhibitor in ovarian cancer cell models. Two chemosensitive human ovarian cancer cell lines, HeyA8 and SKOV3ip1, were used to study the effects of aurora kinase inhibition. Additionally two chemoresistant cell lines (Hey A8-MDR and A2780-CP-20) were also studied. Both cell lines showed that aurora kinase inhibition alone significantly reduced tumor burden. Combination treatment with docetaxel resulted in significantly improved reduction in tumor growth beyond that afforded by docetaxel alone (P < or = .03). Scharer et al. [97] also reported that aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. Manfredl et al. [98] reported the antitumor activity of MLN8054, an orally active small molecule inhibitor of aurora kinase. Growth of human tumor xenografts in nude mice was dramatically inhibited after oral administration of MLN8054 in human tumor xenografts. MLN8054 induced mitotic accumulation and apoptosis. Given these findings MLN8054 is currently being explored in the management of patients with platinum-refractory or resistant epithelial, fallopian, or primary peritoneal carcinoma (NCT00853307). 11. Hedgehog Pathway Inhibitors Hedgehog signaling plays a role in many processes such as cell differentiation, growth, and proliferation. This pathway is active during embryonic development and remains active in the adult where it is involved in the maintenance of stem cell populations. The Hedgehog family [99] has several proteins which function as signaling molecules. These include Sonic hedgehog (Shh), Indian hedgehog (Ihh), and Desert hedgehog (Dhh). There are two receptors that are involved in the Hedgehog pathway. PATCHED1 is a hedgehog receptor. In the absence of a ligand PATCHED1 inhibits SMOOTHENED, a transmembrane G-coupled protein. However, when the ligand binds PATCHED1, SMOOTHENED suppression is relieved resulting in transcription of the Hedgehog genes. PATCHED1 or Journal of Oncology 7 Table 4: PARP inhibitors and ovarian cancer. clinical trial.gov ID NCT00753545 NCT00679783 NCT00749502 NCT00664781 NCT00647062 Therapeutic regimen AZD2281 in platinum sensitive EOC AZD2281 in known BRCA or recurrent EOC MK4827 in BRCA mutant ovarian cancer AG014699 in BRCA mutant ovarian cancer AZD2281 and carboplatin in BRCA mutant EOC SMOOTHENED receptor mutations or overexpression of the Hedgehog ligand leads to uncontrolled cell proliferation. Bhattacharya et al. [99] studied the role of Hedgehog signaling in ovarian cancer. They utilized a hedgehog pathway blocker and studied the proliferation of ovarian tumors. They noted that PATCHED1 is downregulated in ovarian cancer and that this low level expression of the PATCHED1 contributed to the proliferation of ovarian cancer cells. Chen et al. [100] also examined the expression and the functional role of the hedgehog signal molecules in ovarian cancer. They reported that the hedgehog molecules (Shh, Dhh, Ptch, Smo, and Gli 1 proteins) were increased in malignant disease. Decreased cell proliferation in ovarian carcinoma cell lines was observed with Hedgehog pathway inhibitorcyclopamine. Recently reported was the effect of IPI-926 (Infinity Pharmaceuticals, Inc., Cambridge, Mass) a novel inhibitor of the Hedgehog signaling pathway in ovarian cancer grafts. Data revealed that treatment with cyclopamine, the natural product of IPI-926 in animals with primary ovarian cancer grafts, resulted in tumor growth inhibition. This agent is currently being explored as a Phase I study in patients with solid tumors (NCT00761696). Currently recruiting is a study of GDC-0449 (Genentech, Inc), a Hedgehog pathway inhibitor, as maintenance therapy in patients with ovarian cancer in a second or third complete remission. GDC-0449 will be evaluated in approximately 100 patients with ovarian cancer in second or third complete remission in a randomized, placebo-controlled, doubleblind, multicenter Phase II trial. Patients are randomized in a 1 : 1 ratio to receive either GDC-0449 or a placebo comparator and are stratified based on whether their cancer is in a second or third complete remission. The primary endpoint of the trial is progression-free survival. Secondary outcome measures include overall survival, measurement of Hedgehog ligand expression in archival tissue, and number and attribution of adverse events. 12. MTOR Inhibitors Numerous investigators have reported alterations in PTEN in gynecological malignancies [101]. PTEN is a lipid phosphatase that is associated with cell cycle G1-phase arrest and apoptosis through the PI3K/AKT/mTOR pathway [102]. The mTOR pathway is a central regulator of cell growth, proliferation, and apoptosis. The loss of functional PTEN either through deletion, mutation, or inactivation leads to the constitutive activation of PI3K effectors in the absence of exogenous stimuli. Potential therapies targeting the mTOR Study PI J. Lederman K. Gelman R. Plummer E. Kohn pathway include mTOR inhibitors Temsirolimus (CCI-779), everolimus (RAD001), and deforolimus (AP23573). In ovarian cancer, AKT activity is frequently elevated and is closely associated with the upregulation of mTOR signaling [103]. High levels of AKT activity in vitro result in hypersensitivity to mTOR inhibitors [103]. An in vivo study [104] using xenografts of SKOV-3 cells revealed that RAD001 inhibited tumor growth, angiogenesis, and production of ascites suggesting the potential of mTOR inhibitors in the treatment of women with ovarian cancer. GOG trial 170I has recently closed a Phase II Evaluation of Temsirolimus (CCI-779, mTOR inhibitor) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma. Currently recruiting studies include (NCT00926107), a study of the mTOR inhibitor Temsirolimus (CCI-779) to treat ovarian cancer with Ca125 relapse only, a Phase I study of DOXIL and Temsirolimus in Resistant Solid Malignancies NCT00703170, and a Phase I study of Docetaxel and Temsirolimus in resistant solid malignancies (NCT00703625). 13. Conclusion Multiple attractive targets for the design of targeted therapeutics in ovarian cancer are currently under investigation. Recent studies employing monoclonal antibodies have revealed improvements in time to progression. Studies with tyrosine kinases inhibitors remain in their infancy of development but have provided the basis for continued research. Despite these advances there are multiple goals for the future. These include a better understanding of the redundant pathways that exist in cell signaling, creative targeting of horizontal and vertical signaling pathways, identification of other predictive markers to better identify a targeted subpopulation of patients that will respond, and an underlying of the mechanisms of resistance. Achieving these goals will be of paramount importance in the study of targeted therapy in ovarian cancer. References [1] M. A. Bookman, K. M. Darcy, D. Clarke-Pearson, R. A. Boothby, and I. R. Horowitz, “Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group,” Journal of Clinical Oncology, vol. 21, no. 2, pp. 283–290, 2003. 8 [2] M. S Gordon, D. Matei, C. Aghajanian, et al., “Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status,” Journal of Clinical Oncology, vol. 23, no. 16S, 2005, abstract 5051. [3] M. V. Seiden, H. A. Burris, U. Matulonis, et al., “A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies,” Gynecologic Oncology, vol. 104, no. 3, pp. 727–731, 2007. [4] E. M. Posadas, M. S. Liel, V. Kwitkowski, et al., “A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer,” Cancer, vol. 109, no. 7, pp. 1323–1330, 2007. [5] A. N. Gordon, N. Finkler, R. P. Edwards, et al., “Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study,” International Journal of Gynecological Cancer, vol. 15, no. 5, pp. 785–792, 2005. [6] S. Campos, O. Hamid, M. V. Seiden, et al., “Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5597–5604, 2005. [7] R. A. Burger, M. W. Sill, B. J. Monk, B. E. Greer, and J. I. Sorosky, “Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5165–5171, 2007. [8] S. A. Cannistra, U. A. Matulonis, R. T. Penson, et al., “Phase II study of bevacizumab in patients with platinumresistant ovarian cancer or peritoneal serous cancer,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5180–5186, 2007. [9] A. A. Garcia, H. Hirte, G. Fleming, et al., “Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia,” Journal of Clinical Oncology, vol. 26, no. 1, pp. 76–82, 2008. [10] J. D. Wright, A. Hagemann, J. S. Rader, et al., “Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma,” Cancer, vol. 107, no. 1, pp. 83– 89, 2006. [11] J. C. Chura, K. Van Iseghem, L. S. Downs Jr., L. F. Carson, and P. L. Judson, “Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer,” Gynecologic Oncology, vol. 107, no. 2, pp. 326–330, 2007. [12] H. S. Nimeiri, A. M. Oza, R. J. Morgan, et al., “Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia,” Gynecologic Oncology, vol. 110, no. 1, pp. 49–55, 2008. [13] B. J. Monk, E. Han, C. A. Josephs-Cowan, G. Pugmire, and R. A. Burger, “Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer,” Gynecologic Oncology, vol. 102, no. 2, pp. 140–144, 2006. [14] F. Simpkins, J. L. Belinson, P. G. Rose, et al., “Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening,” Gynecologic Oncology, vol. 107, no. 1, pp. 118–123, 2007. [15] K. F. McGonigle, H. G. Muntz, J. L. Vuky, et al., “A phase II prospective study of weekly topotecan and bevacizumab Journal of Oncology [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] in platinum refractory ovarian cancer or peritoneal cancer,” Journal of Clinical Oncology, vol. 26, 2008, abstract 5551. J. P. Micha, B. H. Goldstein, M. A. Rettenmaier, et al., “A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer,” International Journal of Gynecological Cancer, vol. 17, no. 4, pp. 771–776, 2007. N. S. Azad, E. M. Posadas, V. E. Kwitkowski, et al., “Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity,” Journal of Clinical Oncology, vol. 26, no. 22, pp. 3709–3714, 2008. R. T. Penson, S. Cannistra, M. V. Seiden, et al., “Phase II study of carboplatin, paclitaxel and bevacizumab as first line therapy and consolidation for advanced mullerian tumors,” Journal of Clinical Oncology, vol. 24, no. 18S, 2006, abstract 5020. S. C. Campos, D. S. Dizon, S. A. Cannistra, et al., “Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian mullerian cancers,” Journal of Clinical Oncology, vol. 25, no. 18S, 2007, abstract 5517. S. M. Campos, R. T. Penson, U. Matulonis, et al., “STAC: a randomized phase II trial of avastin or avastin + erlotinib as first line consolidation chemotherapy after standard therapy,” British Gynecological Society Meeting, 2008, abstract 93. U. A. Matulonis, S. Berlin, P. Ivy, et al., “Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube and peritoneal cancer,” Journal of Clinical Oncology, vol. 27, no. 33, pp. 5601–5606, 2009. H. W. Hirte, L. Vidal, G. F. Fleming, et al., “A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer. Final results of a PMH, Chicago and California consortia trial,” Journal of Clinical Oncology, vol. 26, no. 298S, 2008, abstract 5521. R. Buckstein, R. M. Meyer, L. Seymour, et al., “Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND. 182–185,” Current Oncology, vol. 14, no. 4, pp. 154–161, 2007. M. Friedlander, K. C. Hancock, B. Benigno, et al., “Pazopanib (GW 786034) is active in women with advanced epithelial ovarian, fallopian tube, and peritoneal cancers: results of a phase II study,” Journal of Clinical Oncology, vol. 25, no. 18S, 2007, abstract 5561. J. J. Biagi, A. M. Oza, R. Grimshaw, et al., “A phase II study of sunitinib (SU11248) in patients with recurrent epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma-NCIC CTG IND 185,” Journal of Clinical Oncology, vol. 26, 2008, abstract 5522. D. Matei, M. W. Still, K. DeGeest, et al., “Phase II study of sorafenib in persistent or recurrent epithelial ovarian cancer( EOC) or primary peritoneal cancer ( PPC): a Gynecology Oncology Group (GOG) study,” Journal of Clinical Oncology, vol. 26, 2008, abstract 5537. E. J. Battegay, “Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects,” Journal of Molecular Medicine, vol. 73, no. 7, pp. 333–346, 1995. J. Folkman, “Angiogenesis in cancer, vascular, rheumatoid and other disease,” Nature Medicine, vol. 1, no. 1, pp. 27–31, 1995. H. C. Hollingsworth, E. C. Kohn, S. M. Steinberg, M. L. Rothenberg, and M. J. Merino, “Tumor angiogenesis in advanced stage ovarian carcinoma,” The American Journal of Pathology, vol. 147, no. 1, pp. 33–41, 1995. Journal of Oncology [30] H. F. Dvorak, “Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy,” Journal of Clinical Oncology, vol. 20, no. 21, pp. 4368–4380, 2002. [31] J. Folkman, “Tumor angiogenesis: therapeutic implications,” The New England Journal of Medicine, vol. 285, no. 21, pp. 1182–1186, 1971. [32] N. Ferrara, “Role of vascular epidermal growth factor in regulation of angiogenesis,” Kidney International, vol. 56, no. 3, pp. 794–814, 1995. [33] A. A. Alvarez, H. R. Krigman, R. S. Whitaker, R. K. Dodge, and G. C. Rodriguez, “The prognostic significance of angiogenesis in epithelial ovarian carcinoma,” Clinical Cancer Research, vol. 5, no. 3, pp. 587–591, 1999. [34] G. Gasparini, E. Bonoldi, G. Viale, et al., “Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas,” International Journal of Cancer, vol. 69, no. 3, pp. 205–211, 1996. [35] G. H. Shen, M. Ghazizadeh, O. Kawanami, et al., “Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma,” British Journal of Cancer, vol. 83, no. 2, pp. 196–203, 2000. [36] M. Sönmezer, M. Güngör, A. Ensari, and F. Ortaç, “Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor β and vascular endothelial growth factor,” International Journal of Gynecological Cancer, vol. 14, no. 1, pp. 82–88, 2004. [37] P. J. Paley, K. A. Staskus, K. Gebhard, et al., “Vascular endothelial growth factor expression in early stage ovarian carcinoma,” Cancer, vol. 80, no. 1, pp. 98–106, 1997. [38] E. M. Hartenbach, T. A. Olson, J. J. Goswitz, et al., “Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas,” Cancer Letters, vol. 121, no. 2, pp. 169–175, 1997. [39] N. Colombo, G. Mangili, S. Mammoliti, et al., “Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: preliminary results of a pilot study,” Journal of Clinical Oncology, vol. 26, 2008, abstract 14598. [40] W. Tew, N. Colombo, I. Ray-Caquard, et al., “VEGF-Trap for patients with recurrent platinum resistant epithelial ovarian cancer,” Journal of Clinical Oncology, vol. 25, no. 18S, 2008, abstract 5508. [41] D. S. Alberts, P. Y. Liu, E. V. Hannigan, et al., “Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer,” The New England Journal of Medicine, vol. 335, no. 26, pp. 1950–1955, 1996. [42] M. Markman, B. N. Bundy, D. S. Alberts, et al., “Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group,” Journal of Clinical Oncology, vol. 19, no. 4, pp. 1001–1007, 2001. [43] D. K. Armstrong, B. Bundy, L. Wenzel, et al., “Intraperitoneal cisplatin and paclitaxel in ovarian cancer,” The New England Journal of Medicine, vol. 354, no. 1, pp. 34–43, 2006. [44] J. A. Konner, D. Grabon, S. Pezzulli, et al., “A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy 9 [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer,” Journal of Clinical Oncology, vol. 27, no. 15S, 2009, abstract 5539. D. D. McMeekin, G. Lanneau, J. Curiel, et al., “Phase II study of intravenous (IV) bevacizumab and paclitaxel, and intraperitoneal (IP) cisplatin, followed by bevacizumab consolidation for advanced ovarian (O) or peritoneal (P) cancers,” Journal of Clinical Oncology, vol. 27, no. 15S, 2009, abstract 5540. E. Pujade-Lauraine, S. Mahner, J. Kaern, et al., “A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG),” Journal of Clinical Oncology, vol. 27, no. 18S, 2009, abstract LBA5509. J. Mendelsohn and J. Baselga, “The EGF receptor family as targets for cancer therapy,” Oncogene, vol. 19, no. 56, pp. 6550–6565, 2000. B. F. El-Rayes and P. M. LoRusso, “Targeting the epidermal growth factor receptor,” British Journal of Cancer, vol. 91, no. 3, pp. 418–424, 2004. R. Nahta and F. J. Esteva, “HER-2-targeted therapy: lessons learned and future directions,” Clinical Cancer Research, vol. 9, no. 14, pp. 5078–5084, 2003. M. A. Bookman, “Biological therapy of ovarian cancer: current directions,” Seminars in Oncology, vol. 25, no. 3, pp. 381–396, 1998. S. B. Kaye, C. J. Poole, M. Bidzinksi, et al., “A randomized phase II study evaluating the combination of carboplatinbased chemotherapy with pertuzumab versus carboplatin based chemotherapy in patients with relapsed platinum sensitive ovarian cancer,” Journal of Clinical Oncology, vol. 26, 2008, abstract 5520. L. Amler, S. Makhija, and T. Januario, “Her 2 pathway gene expression analysis in a phase II study of pertuzumab+ gemcitabine vs. gemcitabine + placebo in patients with platinum resistant epithelial ovarian cancer,” Journal of Clinical Oncology, vol. 26, 2008, abstract 5562. S. Makhija, D. Glenn, F. Ueland, et al., “Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer,” Journal of Clinical Oncology, vol. 25, no. 18S, 2007, abstract 5507. M. S. Gordon, D. Matei, C. Aghajanian, et al., “Clinical activity of pertuzumab (rhuMAb2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predicative relationship between tumor HER 2 activation status,” Journal of Clinical Oncology, vol. 24, no. 26, pp. 4324–4332, 2006. R. J. Schilder, M. V. Sill, W. Chen, et al., “Phase II study of Getinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecological Oncology Group Study,” Clinical Cancer Research, vol. 11, no. 15, pp. 5539–5548, 2005. B. Tanner, D. Hasenclever, K. Stern, et al., “ErbB-3 predicts survival in ovarian cancer,” Journal of Clinical Oncology, vol. 24, no. 26, pp. 4317–4323, 2006. R. S. Herbst, D. H. Johnson, E. Mininberg, et al., “Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell 10 [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] Journal of Oncology lung cancer,” Journal of Clinical Oncology, vol. 23, no. 11, pp. 2544–2555, 2005. J. Andrae, R. Gallini, and C. Betsholtz, “Role of plateletderived growth factors in physiology and medicine,” Genes & Development, vol. 22, no. 10, pp. 1276–1312, 2008. J. Schmitt and D. Matei, “Platelet-derived growth factor pathway inhibitors in ovarian cancer,” Clinical Ovarian Cancer, vol. 1, no. 2, pp. 120–126, 2008. X. Mao and R. A. Hamoudi, “Molecular and cytogenetic analysis of glioblastoma multiforme,” Cancer Genetics and Cytogenetics, vol. 122, no. 2, pp. 87–92, 2000. M. Carroll, M. H. Tomasson, G. F. Barker, T. R. Golub, and D. G. Gilliland, “The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase-dependent signaling pathways,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 25, pp. 14845–14850, 1996. M. C. Heinrich, C. L. Corless, A. Duensing, et al., “PDGFRA activating mutations in gastrointestinal stromal tumors,” Science, vol. 299, no. 5607, pp. 708–710, 2003. S. M. Apte, C. D. Bucana, J. J. Killion, D. M. Gershenson, and I. J. Fidler, “Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines,” Gynecologic Oncology, vol. 93, no. 1, pp. 78–86, 2004. R. L. Coleman, R. R. Broaddus, D. C. Bodurka, et al., “Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers,” Gynecologic Oncology, vol. 101, no. 1, pp. 126–131, 2006. E. M. Posadas, V. Kwitkowski, H. L. Kotz, et al., “A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling,” Cancer, vol. 110, no. 2, pp. 309–317, 2007. D. Matei, D. D. Chang, and M.-H. Jeng, “Imatinib mesylate (Gleevac) inhibits ovarian cancer cell growth through a mechanisms dependent on platelet derived growth factor α and Akt inactivation,” Clinical Cancer Research, vol. 10, no. 2, pp. 681–690, 2004. E. Buchdunger, J. Zimmermann, H. Mett, et al., “Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylamniopyridmidine class,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 7, pp. 2558–2562, 1995. H. Youssoufian, R. J. Amato, C. J. Sweeney, et al., “Phase I study of IMC-3G3, and IgG1 monoclonal antibody targeting PDGFRα in patients with advanced solid malignancies,” Journal of Clinical Oncology, vol. 26, no. 636S, 2008. G. C. Jayson, G. J. M. Parker, S. Mullamitha, et al., “Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab’, leads to fluid accumulation and is associated with increased tumor vascularized volume,” Journal of Clinical Oncology, vol. 23, no. 5, pp. 973–981, 2005. R. J. Schilder, M. W. Sill, R. B. Lee, et al., “Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study,” Journal of Clinical Oncology, vol. 26, no. 20, pp. 3418–3425, 2008. D. S. Alberts, P. Y. Liu, S. P. Wilczynski, et al., “Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer,” International Journal of Gynecological Cancer, vol. 17, no. 4, pp. 784–788, 2007. [72] F. Hilberg, G. J. Roth, M. Krssak, et al., “BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy,” Cancer Research, vol. 68, no. 12, pp. 4774–4782, 2008. [73] J. A. Ledermann, G. J. Rustin, A. Hackshaw, et al., “A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC),” Journal of Clinical Oncology, vol. 27, no. 15S, 2009, abstract 5501. [74] S. Markert, S. Lassmann, B. Gabriel, et al., “Alpha-folate receptor expression in epithelial ovarian carcinoma and nonneoplastic ovarian tissue,” Anticancer Research, vol. 28, no. 6, pp. 3567–3572, 2008. [75] H. Elnakat and M. Ratnam, “Role of folate receptor genes in reproduction and related cancers,” Frontiers in Bioscience, vol. 11, pp. 506–519, 2006. [76] K. R. Kalli, A. L. Oberg, G. L. Keeney, et al., “Folate receptor alpha as a tumor target in epithelial ovarian cancer,” Gynecologic Oncology, vol. 108, pp. 619–626, 2008. [77] K. L. Knutson, C. J. Krco, C. L. Erskine, et al., “T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer,” Journal of Clinical Oncology, vol. 24, no. 26, pp. 4254–4261, 2006. [78] J. J. Hernando, T.-W. Park, H.-P. Fischer, et al., “Vaccination with dendritic cells transfected with mRNA-encoded folatereceptor-α for relapsed metastatic ovarian cancer,” The Lancet Oncology, vol. 8, no. 5, pp. 451–454, 2007. [79] W. Ebel, E. L. Routhier, B. Foley, et al., “Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha,” Cancer Immunity, vol. 7, pp. 6–13, 2007. [80] D. K. Armstrong, A. Bicher, R. L. Coleman, et al., “Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinumsensitive ovarian cancer in first relapse,” Journal of Clinical Oncology, vol. 26, 2008, abstract 5500. [81] D. Ford, D. F. Easton, D. T. Bishop, S. A. Narod, and D. E. Goldgar, “Risks of cancer in BRCA1-mutation carriers,” The Lancet, vol. 343, no. 8899, pp. 692–695, 1994. [82] C. J. Lord and A. Ashworth, “Targeted therapy for cancer using PARP inhibitors,” Current Opinion in Pharmacology, vol. 8, no. 4, pp. 363–369, 2008. [83] A. N. J. Tutt, C. J. Lord, N. McCabe, et al., “Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer,” Cold Spring Harbor Symposia on Quantitative Biology, vol. 70, pp. 139–148, 2005. [84] P. C. Fong, D. S. Boss, C. P. Carden, et al., “AZD2281 [KU0059436], a PARP [poly ADP-ribose polymerase] inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study,” Journal of Clinical Oncology, vol. 26, 2008, abstract 5510. [85] C. Carden, et al., “Phase I study of AZD2281 [KU-0059436], a PARP [poly ADP-ribose polymerase] inhibitor: results in patients with BRCA deficient ovarian cancer,” in Proceedings of the National Cancer Research Institute Cancer Conference, vol. 320, 2008, abstract BOA22. [86] M. W. Audeh, R. T. Penson, M. Friedlander, et al., “Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer,” Journal of Clinical Oncology, vol. 27, no. 15S, 2009, abstract 5500. [87] J. Z. Press, A. De Luca, N. Boyd, et al., “Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities,” BMC Cancer, vol. 8, article 17, 2008. Journal of Oncology [88] E. A. Harrington, D. Bebbington, J. Moore, et al., “VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo,” Nature Medicine, vol. 10, no. 3, pp. 262–267, 2004. [89] N. Keen and S. Taylor, “Aurora-kinase inhibitors as anticancer agents,” Nature Reviews Cancer, vol. 4, no. 12, pp. 927– 936, 2004. [90] N. Matthews, C. Visintin, B. Hartzoulakis, A. Jarvis, and D. L. Selwood, “Aurora A and B kinases as targets for cancer: will they be selective for tumors?” Expert Review of Anticancer Therapy, vol. 6, no. 1, pp. 109–120, 2006. [91] H. Zhou, J. Kuang, L. Zhong, et al., “Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation,” Nature Genetics, vol. 20, no. 2, pp. 189–193, 1998. [92] H. Katayama, K. Sasai, H. Kawai, et al., “Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53,” Nature Genetics, vol. 36, no. 1, pp. 55–62, 2004. [93] C. N. Landen Jr., Y. G. Lin, A. Immaneni, et al., “Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients,” Clinical Cancer Research, vol. 13, no. 14, pp. 4098–4104, 2007. [94] M. M. Tanner, S. Grenman, A. Koul, et al., “Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer,” Clinical Cancer Research, vol. 6, no. 5, pp. 1833–1839, 2000. [95] A. A. Kulkarni, M. Loddo, E. Leo, et al., “DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma,” Clinical Cancer Research, vol. 13, no. 20, pp. 6153–6161, 2007. [96] Y. G. Lin, A. Immaneni, W. M. Merritt, et al., “Targeting Aurora kinase with MK-0457 inhibits ovarian cancer growth,” Clinical Cancer Research, vol. 14, no. 17, pp. 5437– 5446, 2008. [97] C. D. Scharer, N. Laycock, A. O. Osunkoya, et al., “Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells,” Journal of Translational Medicine, vol. 6, article 79, 2008. [98] M. G. Manfredi, J. A. Ecsedy, K. A. Meetze, et al., “Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora a kinase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 10, pp. 4106–4111, 2007. [99] R. Bhattacharya, J. Kwon, B. Ali, et al., “Role of hedgehog signaling in ovarian cancer,” Clinical Cancer Research, vol. 14, no. 23, pp. 7659–7666, 2008. [100] X. Chen, A. Horiuchi, N. Kikuchi, et al., “Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: it’s inhibition leads to growth suppression and apoptosis,” Cancer Science, vol. 98, no. 1, pp. 68–76, 2007. [101] B. H. Jiang and L. Z. Liu, “PI3K/PTEN signaling in tumorgenesis and angiogenesis,” Biochimica et Biophysica Acta, vol. 1784, no. 1, pp. 150–158, 2008. [102] I. Sansal and W. R. Sellers, “The biology and clinical relevance of the PTEN tumor suppressor pathway,” Journal of Clinical Oncology, vol. 22, no. 14, pp. 2954–2963, 2004. [103] J .F. Gera, I. K. Mellinghoff, Y. Shi, et al., “AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D and c-myc expression,” The Journal of Biological Chemistry, vol. 279, no. 4, pp. 2737–2746, 2004. [104] S. Mabuchi, D. A. Altomare, M. Cheung, et al., “RAD001 inhibits human ovarian cancer cell proliferation, enhances 11 cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model,” Clinical Cancer Research, vol. 13, no. 14, pp. 4261–4270, 2007. MEDIATORS of INFLAMMATION The Scientiic World Journal Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 Gastroenterology Research and Practice Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 Journal of Diabetes Research Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 International Journal of Journal of Endocrinology Immunology Research Hindawi Publishing Corporation http://www.hindawi.com Disease Markers Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 Volume 2014 Submit your manuscripts at http://www.hindawi.com BioMed Research International PPAR Research Hindawi Publishing Corporation http://www.hindawi.com Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 Volume 2014 Journal of Obesity Journal of Ophthalmology Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 Evidence-Based Complementary and Alternative Medicine Stem Cells International Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 Journal of Oncology Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 Parkinson’s Disease Computational and Mathematical Methods in Medicine Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 AIDS Behavioural Neurology Hindawi Publishing Corporation http://www.hindawi.com Research and Treatment Volume 2014 Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 Oxidative Medicine and Cellular Longevity Hindawi Publishing Corporation http://www.hindawi.com Volume 2014